抗凝治疗肝硬化患者并发门静脉血栓的循证医学证据*

doi:10.3969/j.issn.1672-5069.2016.05.032

摘要/Abstract

摘要： 门静脉血栓（PVT）对肝硬化患者的预后有着不良的影响，因此需要给予恰当的处理。临床上常用的治疗策略为抗凝治疗，但是考虑到肝硬化伴有PVT患者食管胃底静脉曲张破裂出血的风险比无肝病的原发性PVT患者要高很多，抗凝治疗的选择十分困难。大多指南对于肝硬化并发PVT患者应当如何治疗并未作出明确的推荐。我们通过检索相关临床研究发现，在肝硬化PVT患者应用抗凝药物能获得较高的再通率，而不会显著增加出血的风险，但研究的证据级别普遍较低，需要更多的前瞻性、大样本研究以进一步论证，同时临床应用抗凝治疗时仍需根据患者的具体情况进行个体化的治疗。

关键词: 肝硬化, 门静脉血栓, 抗凝治疗

Abstract: Portal vein thrombosis（PVT） should be treated properly because it has an objective effect on the prognosis of patients with cirrhosis. Anticoagulant therapy is commonly used in clinic，but how to make the correct choice of it for patients with risk of variceal bleeding is very hard. The current worldwide guidelines for the management of cirrhosis patients with PVT do not provide a definite recommendation. We retrieved the relevant clinical trials in literatures and found that the application of anticoagulation in cirrhosis patients with PVT was associated with a high rates of recanalization and didn’t increase the risk of gastrointestinal bleeding. The evidences of current research，however，are generally at a very low levels，and more prospective studies with relatively large samples are needed to give a confirmed conclusion. We think the use of anticoagulant therapy should be individualized based on the specific circumstances at present.

Key words: Liver cirrhosis, Portal vein thrombosis, Anticoagulant therapy

陆申新综述，陈世耀审校. 抗凝治疗肝硬化患者并发门静脉血栓的循证医学证据*[J]. 实用肝脏病杂志, 2016, 19(5): 624-628.

Lu Shenxin，Chen Shiyao.. Anticoagulant therapy in patients with liver cirrhosis complicated by portal vein thrombosis:evidence-based medicine[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 624-628.

参考文献

[1] Ponziani FR,Zocco MA,Garcovich M,et al. What we should know about portal vein thrombosis in cirrhotic patients:a changing perspective. World J Gastroenterol, 2012,18（36）:5014-5020.
[2] Tsochatzis EA,Senzolo M,Germani G,et al. Systematic review:portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther,2010,31（3）:366-374.
[3] Deleve LD,Valla DC,Garcia-Tsao G. Vascular disorders of the liver. Hepatology,2009,49（5）:1729-1764.
[4] Amitrano L,Guardascione MA. Management of portal vein thrombosis in cirrhotic patients. Mediterr J Hematol Infect Dis, 2009,1（3）:e2009014.
[5] Luca A,Caruso S,Milazzo M,et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology,2012,265（1）:124-132.
[6] Maruyama H,Okugawa H,Takahashi M,et al. De novo portal vein thrombosis in virus-related cirrhosis:predictive factors and long-term outcomes. Am J Gastroenterol,2013,108（4）:568-574.
[7] Senzolo M,Sartori MT,Rossetto V,et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int,2012,32（6）:919-927.
[8] Delgado MG,Seijo S,Yepes I,et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol,2012,10（7）:776-783.
[9] Amitrano L,Guardascione MA,Menchise A,et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol,2010,44（6）:448-451.
[10] Werner KT,Sando S,Carey EJ,et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation:outcome of anticoagulation. Dig Dis Sci,2013,58（6）:1776-1780.
[11] Maruyama H,Takahashi M,Shimada T,et al. Emergency anticoagulation treatment for cirrhosis patients with portal vein thrombosis and acute variceal bleeding. Scand J Gastroenterol,2012,47（6）:686-691.
[12] Naeshiro N,Aikata H,Hyogo H,et al. Efficacy and safety of the anticoagulant drug,danaparoid sodium,in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res,2015,45（6）:656-662.
[13] Francoz C,Belghiti J,Vilgrain V,et al. Splanchnic vein thrombosis in candidates for liver transplantation:usefulness of screening and anticoagulation. Gut,2005,54（5）:691-697.
[14] Englesbe MJ,Kubus J,Muhammad W,et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl,2010,16（1）:83-90.
[15] Lendoire J,Raffin G,Cejas N,et al. Liver transplantation in adult patients with portal vein thrombosis:risk factors,management and outcome. HPB （Oxford）,2007,9（5）:352-356.
[16] Rodriguez-Castro KI,Simioni P,Burra P,et al. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int,2012,32（10）:1465-1476.
[17] Qi X,Bai M,Yang Z,et al. Occlusive portal vein thrombosis as a new marker of decompensated cirrhosis. Med Hypotheses,2011,76（4）:522-526.
[18] Englesbe MJ,Schaubel DE,Cai S,et al. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl,2010,16（8）:999-1005.
[19] de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop:stratifying risk and individualizing care for portal hypertension. J Hepatol,2015,63（3）:743-752.
[20] Qi X,De Stefano V,Li H,et al. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis:a systematic review and meta-analysis of observational studies. Eur J Intern Med,2015,26（1）:23-29.
[21] Yang ZJ,Costa KA,Novelli EM,et al. Venous thromboembolism in cirrhosis. Clin Appl Thromb Hemost,2014,20（2）:169-178.
[22] Kovacs MJ,Wong A,Mackinnon K,et al. Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost,1994,71（6）:727-730.
[23] Pellicelli AM. Portal vein thrombosis in cirrhotic patients:safety and efficacy of low dosage of enoxiparin. J Hepatol,2010,52（S）:S80.
[24] Cui SB,Shu RH,Yan SP,et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol,2015,27（8）:914-919.
[25] Baglin T,Barrowcliffe TW,Cohen A,et al. Guidelines on the use and monitoring of heparin. Br J Haematol,2006,133（1）:19-34.
[26] Bechmann LP,Sichau M,Wichert M,et al. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int,2011,31（1）:75-82.
[27] Lisman T,Bijsterveld NR,Adelmeijer J,et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost,2003,1（11）:2368-2373.
[28] Senzolo M,Rodriguez-Castro KI,Rossetto V,et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost,2012,10（9）:1823-1829.
[29] Lisman T,Porte RJ. Towards a rational use of low-molecular-weight heparin in patients with cirrhosis. Liver Int,2011,31（7）:1063.
[30] Martinez M,Tandra A,Vuppalanchi R. Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology,2014,60（1）:425-426.
[31] Pannach S,Babatz J,Beyer-Westendorf J. Successful treatment of acute portal vein thrombosis with rivaroxaban. Thromb Haemost,2013,110（4）:626-627.
[32] Lenz K,Dieplinger B,Buder R et al. Successful treatment of partial portal vein thrombosis （PVT） with low dose rivaroxaban. Z Gastroenterol,2014,52（10）:1175-1177.
[33] Potze W,Adelmeijer J,Lisman T. Decreased in vitro anticoagulant potency of rivaroxaban and apixaban in plasma from patients with cirrhosis. Hepatology,2015,61（4）:1435-1436.
[34] Qi X,Han G,Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol,2014,11（7）:435-446.
[35] Perarnau JM,Baju A,D'Alteroche L,et al. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis. Eur J Gastroenterol Hepatol,2010,22（9）:1093-1098.
[36] Qi X,Han G,He C,et al. Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhotic patients with non-tumoral portal vein thrombosis:a hypothesis. Med Sci Monit,2012,18（8）:HY37-41.
[37] Ponziani FR,Zocco MA,Campanale C,et al. Portal vein thrombosis:insight into physiopathology,diagnosis,and treatment. World J Gastroenterol,2010,16（2）:143-155.
[38] Smalberg JH,Spaander MV,Jie KS,et al. Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis. Thromb Haemost,2008,100（6）:1084-1088.
[39] De Santis A,Moscatelli R,Catalano C,et al. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients:a pilot